Last reviewed · How we verify
GP404141
GP404141 is a small molecule drug that targets the S1P receptor.
GP404141 is a small molecule drug that targets the S1P receptor. Used for Multiple sclerosis.
At a glance
| Generic name | GP404141 |
|---|---|
| Also known as | romiplostim |
| Sponsor | Geropharm |
| Drug class | S1P receptor modulator |
| Target | S1P receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
GP404141 works by selectively modulating the sphingosine-1-phosphate (S1P) receptor, which plays a crucial role in the regulation of immune responses. This mechanism of action is thought to contribute to its therapeutic effects in various indications.
Approved indications
- Multiple sclerosis
Common side effects
- Headache
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GP404141 CI brief — competitive landscape report
- GP404141 updates RSS · CI watch RSS
- Geropharm portfolio CI